{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:42:14Z","timestamp":1794138134188,"version":"4.8.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is the most common hematologic malignancy in blacks. Some prior studies suggest inferior survival in blacks; others suggest similar survival. Using the original 9 Surveillance, Epidemiology, and End Results registries, we conducted a large-scale population-based study including 5798 black and 28 939 white MM patients diagnosed 1973-2005, followed through 2006. Age-adjusted incidence rates, disease-specific survival, and relative survival rates were calculated by race, age, and time period of diagnosis. Mean age at diagnosis was 65.8 and 69.8 years for blacks and whites, respectively (P &lt; .001). Incidence among blacks was m twice that among whites; this disparity was greater among patients &lt; 50 years (P = .002). Over the entire study period, disease-specific and relative survival rates were higher in blacks than whites (P &lt; .001). For whites, 5-year relative survival rates increased significantly 1973-1993 to 1994-1998 (26.3% to 30.8%; P &lt; .001) and 1994-1998 to 1999-2005 (30.8% to 35.0%; P = .004). Survival improvements among blacks were smaller and nonsignificant (1973-1993 to 1999-2005: 31.0% to 34.1%; P = .07). We found (1) a younger age of onset among blacks; (2) better survival in blacks 1973-2005; and (3) significant survival improvement among whites over time, with smaller, nonsignificant change seen among blacks, possibly due to unequal access to and\/or disparate responsiveness to novel therapies.<\/jats:p>","DOI":"10.1182\/blood-2010-07-298760","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T00:51:41Z","timestamp":1283907101000},"page":"5501-5506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":360,"title":["Racial disparities in incidence and outcome in multiple myeloma: a population-based study"],"prefix":"10.1182","volume":"116","author":[{"given":"Adam J.","family":"Waxman","sequence":"first","affiliation":[{"name":"Medical Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Mink","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan S.","family":"Devesa","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, NCI, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, NCI, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Medical Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD;"},{"name":"Walter Reed Army Medical Center, Washington, DC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital and Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"McGlynn","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, NCI, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Medical Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111810491487400_B1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1022268103136","article-title":"Myeloma and race: a review of the literature.","volume":"22","author":"Benjamin","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"2019111810491487400_B2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009.","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2019111810491487400_B3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111810491487400_B4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111810491487400_B5","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111810491487400_B6","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients.","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2019111810491487400_B7","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111810491487400_B8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2019111810491487400_B9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111810491487400_B10","first-page":"1860","article-title":"Higher prevalence of monoclonal gammopathy of undetermined significance in African Americans than whites\u2013the unknown role of underlying HIV infection.","volume":"98","author":"Konstantinopoulos","year":"2006","journal-title":"J Natl Med Assoc"},{"issue":"9","key":"2019111810491487400_B11","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.24514","article-title":"Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.","volume":"125","author":"Kristinsson","year":"2009","journal-title":"Int J Cancer"},{"issue":"4","key":"2019111810491487400_B12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","article-title":"Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"2019111810491487400_B13","volume-title":"SEER Cancer Statistics Review, 1975-2007","author":"Altekruse","year":"2010"},{"issue":"9107","key":"2019111810491487400_B14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0140-6736(05)60603-4","article-title":"Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. MRFIT Research Group. Multiple Risk Factor Intervention Trial.","volume":"351","author":"Davey Smith","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"2019111810491487400_B15","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/1097-0142(19841215)54:12<3085::AID-CNCR2820541246>3.0.CO;2-Z","article-title":"Race, poverty, and survival in multiple myeloma.","volume":"54","author":"Savage","year":"1984","journal-title":"Cancer"},{"issue":"10","key":"2019111810491487400_B16","first-page":"1410","article-title":"The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.","volume":"91","author":"Abou-Jawde","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"2019111810491487400_B17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1996.14.3.974","article-title":"Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.","volume":"14","author":"Modiano","year":"1996","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111810491487400_B18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.21139","article-title":"The impact of race on outcomes of autologous transplantation in patients with multiple myeloma.","volume":"83","author":"Verma","year":"2008","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111810491487400_B19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbmt.2009.11.007","article-title":"Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.","volume":"16","author":"Hari","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2019111810491487400_B20","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111810491487400_B21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111810491487400_B22","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111810491487400_B23","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111810491487400_B24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood.V84.3.950.950","article-title":"High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.","volume":"84","author":"Vesole","year":"1994","journal-title":"Blood"},{"issue":"2","key":"2019111810491487400_B25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111810491487400_B26","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma.","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111810491487400_B27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111810491487400_B28","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111810491487400_B29","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111810491487400_B30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"26","key":"2019111810491487400_B31","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111810491487400_B32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111810491487400_B33","first-page":"1117","article-title":"The surveillance, epidemiology, and end results program: a national resource.","volume":"8","author":"Hankey","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2019111810491487400_B34","article-title":"International classification of diseases for oncology: ICD-O.","author":"Fritz","year":"2000","edition":"3rd ed."},{"issue":"5","key":"2019111810491487400_B35","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"24","key":"2019111810491487400_B36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma.","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111810491487400_B37","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"issue":"25","key":"2019111810491487400_B38","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous hematopoietic stem-cell transplantation for multiple myeloma.","volume":"360","author":"Harousseau","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111810491487400_B39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2001.19.1.18","article-title":"Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database.","volume":"19","author":"Anderson","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111810491487400_B40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/aje\/141.4.300","article-title":"Graphical presentation of trends in rates.","volume":"141","author":"Devesa","year":"1995","journal-title":"Am J Epidemiol"},{"issue":"282","key":"2019111810491487400_B41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-Estimation from Incomplete Observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"2019111810491487400_B42","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2307\/2531329","article-title":"The statistical comparison of relative survival rates.","volume":"39","author":"Brown","year":"1983","journal-title":"Biometrics"},{"issue":"5","key":"2019111810491487400_B43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I","article-title":"Contribution of socioeconomic status to black\/white differences in cancer incidence.","volume":"63","author":"McWhorter","year":"1989","journal-title":"Cancer"},{"issue":"7","key":"2019111810491487400_B44","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10552-006-0030-x","article-title":"Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States).","volume":"17","author":"Gebregziabher","year":"2006","journal-title":"Cancer Causes Control"},{"issue":"16","key":"2019111810491487400_B45","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/jama.287.16.2106","article-title":"Survival of blacks and whites after a cancer diagnosis.","volume":"287","author":"Bach","year":"2002","journal-title":"JAMA"},{"issue":"23","key":"2019111810491487400_B46","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/jnci\/djp435","article-title":"StatBite: Multiple myeloma and African Americans: higher incidence but fewer autologous stem cell transplants.","volume":"101","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2019111810491487400_B47","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/COC.0b013e3180592a30","article-title":"Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort.","volume":"30","author":"Rohatgi","year":"2007","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"2019111810491487400_B48","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma.","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/25\/5501\/1461700\/zh805110005501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/25\/5501\/1461700\/zh805110005501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T16:14:03Z","timestamp":1574093643000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/116\/25\/5501\/28669\/Racial-disparities-in-incidence-and-outcome-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,16]]},"references-count":48,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2010,12,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-07-298760","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,16]]}}}